EZH2-EED Binding Inhibitors for PRC2 Disruption in Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EZH2 inhibitors require high doses to effectively inhibit enzyme activity and may cause off-target effects due to non-selective catalytic inhibition, failing to address both catalytic and non-catalytic functions of EZH2 in cancer cells.
Innovation Solution
Development of substituted pyrrolidones and piperidones that selectively target the EZH2-EED interaction, preventing PRC2 complex formation and promoting EZH2 degradation, thereby inhibiting both catalytic and non-catalytic functions of EZH2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EZH2 inhibitors are used to inhibit EZH2 enzyme activity, then catalytic activity is reduced, but non-enzymatic oncogenic functions remain and very high doses are required
Solution Approach 1:
The patent extracts and targets the specific EZH2-EED interaction interface within the PRC2 complex, using small molecules that specifically bind to EZH2 and prevent EED association. This selective extraction of the protein-protein interaction mechanism allows inhibition of both catalytic and non-catalytic functions at lower doses compared to general EZH2 inhibitors
Solution Approach 2:
The invention prevents the formation of the functional PRC2 complex by blocking EZH2-EED interaction before the complex can assemble. By taking preliminary action to disrupt the protein-protein interaction that precedes catalytic activity, the patent achieves comprehensive EZH2 function inhibition including both enzymatic and non-enzymatic oncogenic functions
2Reliability
If EZH2 inhibitors are designed to inhibit catalytic activity, then methyltransferase function is reduced, but PRC2 complex stability and EZH2 retention are maintained
Solution Approach 1:
The patent extracts and specifically targets the EZH2-EED protein-protein interaction interface, using small molecules that bind to EZH2 and prevent EED association. This selective inhibition of the interaction interface disrupts PRC2 complex stability and promotes EZH2 degradation, addressing both catalytic and complex stability aspects
Solution Approach 2:
The invention prevents the formation of the functional PRC2 complex by blocking EZH2-EED interaction before the complex can assemble. By taking preliminary action to disrupt the protein-protein interaction that precedes catalytic activity, the patent achieves comprehensive EZH2 function inhibition including both enzymatic and non-enzymatic oncogenic functions
3Adaptability or versatility
If broad-spectrum EZH2 inhibitors are used, then multiple methyltransferases are inhibited, but off-target effects increase
Solution Approach 1:
The patent applies local quality by designing small molecules with specific structural features (substituted pyrrolidone or piperidone cores with particular substituent patterns) that confer selective binding to the EZH2-EED interface. This localized molecular design enables selective inhibition of EZH2 without affecting other methyltransferases, reducing off-target effects while maintaining targeted efficacy
Data Source
AI summary
Disclosed are substituted pyrrolidones and piperidones which may be utilized as EZH2 targeting agents. The substituted pyrrolidones and piperidones may include substituted 2-pyrrolidones and 2-piperidones. The disclosed pyrrolidones and piperidones may be used in pharmaceutical compositions and methods for treating cell proliferative disorders such as cancer.